Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

NCT05870423 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT05870423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05870423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Lead sponsor
Erasmus Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2022
Completion date
January 1, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors, peptide receptor radionuclide therapy